Aspira Women’s Health Announces OvaSuite(SM) Distribution Agreement in the Philippines
06 Fevereiro 2024 - 10:00AM
Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq:
AWH), a bio-analytical based women’s health company focused on the
development of gynecologic disease diagnostic tools, today
announced the signing of a 5-year distribution agreement granting
Hi-Precision Laboratories the exclusive right to market and
distribute the OvaSuiteSM portfolio in the Philippines. The
commercialization of OvaSuite products in the Philippines will
commence upon receiving approval from the local regulatory
authority. In consideration of the licenses and rights granted by
Aspira, Hi-Precision Laboratories will pay royalties to Aspira for
each test performed in the Philippines.
“We are thrilled to partner with one of the largest medical
laboratories in the Philippines, an important step towards
achieving our goal to make OvaSuite available worldwide,” said
Nicole Sandford, President and Chief Executive Officer of Aspira.
“Moreover, the Clinical Performance of a Multivariate Index Assay
in Detecting Early-Stage Ovarian Cancer in Filipino Women study
clearly demonstrated improvements in the detection of early-stage
ovarian cancers when an Aspira test was incorporated in the
clinical assessment of women presenting with an ovarian mass.”
Vannessa Ongsue, Vice President, Medical Services at
Hi-Precision Laboratories stated, “Hi-Precision is excited to make
the OvaSuite portfolio available to women and clinicians in the
Philippines as research has suggested that women in the Philippines
have a higher risk of ovarian cancer than in other parts of the
world. Aspira’s blood tests are very valuable tools for clinicians
that will lead to a higher standard of care for women in the
Philippines.”
Hi-Precision Laboratories, the largest medical laboratory in the
Philippines, provides a wide array of services from routine to
esoteric specialty tests and is internationally certified and
accredited by the Philippine Accreditation Bureau. With branches
nationwide, Hi-Precision Laboratories conducted 79 million tests
between 2014 and 2022 and has consistently received recognition as
a top-quality service provider in the Philippines.
About Aspira Women’s Health Inc.Aspira Women’s
Health Inc. is dedicated to the discovery, development, and
commercialization of noninvasive, AI-powered tests to aid in the
diagnosis of gynecologic diseases.
OvaWatchSM and Ova1Plus® are offered to clinicians as
OvaSuiteSM. Together, they provide the only comprehensive portfolio
of blood tests to aid in the detection of ovarian cancer for the
1.2+ million American women diagnosed with an adnexal mass each
year. OvaWatch provides a negative predictive value of 99% and is
used to assess ovarian cancer risk for women where initial clinical
assessment indicates the mass is indeterminate or benign, and thus
surgery may be premature or unnecessary. Ova1Plus is comprised of
two FDA-cleared tests, Ova1® and Overa®, to assess the risk of
ovarian malignancy in women planned for surgery.
Our in-development test pipeline is designed to expand our
ovarian cancer portfolio and addresses the tremendous need for
noninvasive diagnostics for endometriosis, a debilitating disease
that impacts millions of women worldwide. In ovarian cancer, our
OvaMDx test is designed to combine microRNA and protein biomarkers
with patient data to further enhance the sensitivity and
specificity of our current tests. In endometriosis, EndoCheckSM is
the first-ever noninvasive test designed to identify endometriomas,
one of the most commonly occurring forms of endometriosis. The
EndoMDxSM test is designed to combine microRNA and protein
biomarkers with patient data to identify all endometriosis.
Forward-Looking StatementsThis press release
may contain forward-looking statements that are made pursuant to
the safe harbor provisions of the federal securities laws,
including those relating to the timing and completion of any
products in the pipeline development that are predictive in nature.
Actual results could differ materially from those discussed due to
known and unknown risks, uncertainties, and other factors. These
forward-looking statements generally can be identified by the use
of words such as “designed to,” “expect,” “plan,” “anticipate,”
“could,” “may,” “intend,” “will,” “continue,” “future,” other words
of similar meaning and the use of future dates. Forward-looking
statements in this press release and other factors that may cause
such differences include the satisfaction of customary closing
conditions related to the offering and the expected timing of the
closing of the offering. These and additional risks and
uncertainties are described more fully in the company’s filings
with the SEC, including those factors identified as “risk factors”
in our most recent Annual Report on Form 10-K and subsequent
Quarterly Reports on Form 10-Q. We are providing this information
as of the date of this press release and do not undertake any
obligation to update any forward-looking statements contained in
this document as a result of new information, future events or
otherwise, except as required by law.
Investor Relations Contact: Torsten Hombeck,
Ph.D.Chief Financial OfficerAspira Women’s
HealthInvestors@aspirawh.com
Aspira Womans Health (NASDAQ:AWH)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Aspira Womans Health (NASDAQ:AWH)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024